Alto Neuroscience (ANRO) Operating Expenses (2023 - 2026)
Alto Neuroscience (ANRO) posted Operating Expenses of $27.1 million for Q1 2026, up 59.12% sequentially from $17.1 million in Q4 2025, and up 73.12% YoY from $15.7 million in Q1 2025.
Alto Neuroscience (ANRO) Operating Expenses (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Operating Expenses for 4 years, with the latest figure at $27.1 million in Q1 2026.
- Quarterly Operating Expenses rose 73.12% year-over-year to $27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.8 million (up 11.34% YoY) and the FY2025 annual result came in at $66.4 million, down 3.27% from the prior year.
- Operating Expenses grew to $27.1 million in Q1 2026 per ANRO's latest filing, from $17.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $27.1 million in Q1 2026 and troughed at $7.2 million in Q1 2023.
- A 4-year average of $15.4 million and a median of $15.7 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 101.0% in 2024, then dropped 20.84% in 2025.
- Over 4 years, Operating Expenses stood at $11.8 million in 2023, then soared by 44.47% to $17.0 million in 2024, then rose by 0.34% to $17.1 million in 2025, then soared by 59.12% to $27.1 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $27.1 million, $17.1 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 29.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.13 Mn |
| Mar 31, 2026 | 27.14 Mn |
| Dec 31, 2025 | 17.06 Mn |
| Sep 30, 2025 | 14.95 Mn |
| Jun 30, 2025 | 18.68 Mn |
| Mar 31, 2025 | 15.68 Mn |
| Dec 31, 2024 | 17.00 Mn |
| Sep 30, 2024 | 18.89 Mn |
| Jun 30, 2024 | 18.34 Mn |
| Mar 31, 2024 | 14.39 Mn |
| Dec 31, 2023 | 11.77 Mn |
| Sep 30, 2023 | 9.72 Mn |
| Jun 30, 2023 | 9.13 Mn |
| Mar 31, 2023 | 7.20 Mn |